CALGARY, Nov. 9 /CNW/ - Orcrist Bio Inc. (ORC) a biotechnology company developing stem cell-mobilizing pharmaceuticals, congratulates Dr. Linda Pilarski on her receipt of the 2009 ASTech Foundation Outstanding Leadership in Alberta Technology Award. This award is presented to an individual or team of individuals who have played a leadership role in and made a contribution to a technological innovation or breakthrough in Alberta. The Alberta Science and Technology (ASTech) Leadership Foundation was created to celebrate and promote the achievements of Alberta's scientific and technological communities. In doing so ASTech is elevating Alberta's status as a science and technology leader, and inspiring future innovation in Alberta (http://www.astech.ab.ca/).
ORC is actively pursuing the commercialization of Dr. Pilarski's intellectual property and technology. ORC has received approval to undertake a Phase I clinical trial with the goal of the study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics (induction of hematopoiesis) of HYC750, a patent-protected formulation of hyaluronan that Dr. Pilarski has made significant contributions towards discovering and developing.
"Orcrist wishes to congratulate Dr. Pilarski on her recognition by the ASTech Foundation with the Outstanding Leadership in Alberta Technology Award," said Dr. Brett Schönekess, President and CEO of Orcrist. "Dr. Pilarski stands in a large peer group of second-to-none science and technology researchers within Alberta, and her recognition as a leader in that group is a significant accomplishment."
About Orcrist Bio Inc.
Orcrist Bio Inc. is a biotechnology company dedicated to developing and commercializing promising therapeutics for areas in which a clear market opportunity exists. ORC's lead program revolves around HYC750, a novel stem cell mobilizer compound that promotes the egress of stem cells and other blood cells from the bone marrow into the blood, from which they can be harvested and applied toward treating chemotherapy-related blood cell depletion. Orcrist is actively looking to add to its pipeline exploring the innate properties of HYC750 and its effects on stem cells, as well as through in-licensing opportunities of other products with clear market potential. ORC is located in Calgary, Alberta. The company is financed by its founders and by private investors.
SOURCE ORCRIST BIO INC.
For further information: For further information: on Orcrist Bio Inc., please see our website www.orcristbio.com. Contact information: Dr. Brett Schonekess, President and CEO, Phone: (403) 984-3882 x 222, Email: firstname.lastname@example.org